Bibliography
- Ali S , CoombesRC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat. Rev. Cancer2 , 101–112 (2002).
- Kurebayashi J . Endocrine-resistant breast cancer: underlying mechanisms and strategies for overcoming resistance. Breast Cancer10 , 112–119 (2003).
- Perou CM , S⊘rlieT, EisenMBet al. Molecular portraits of human breast tumours. Nature 406 , 747–752 (2000).
- Soares J , PintoAE, CunhaCVet al. Global DNA hypomethylation in breast carcinoma: correlation with prognostic factors and tumor progression. Cancer 85 , 112–118 (1999).
- Lo PK , SukumarS. Epigenomics and breast cancer. Pharmacogenomics9 , 1879–1902 (2008).
- Lapidus RG , FergusonAT, OttavianoYLet al. Methylation of estrogen and progesterone receptor gene 5´ CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin. Cancer Res. 2 , 805–810 (1996).
- Dowsett M . Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr. Relat. Cancer8 , 191–195 (2001).
- Bièche I , LidereauR. Genome-based and transcriptome-based molecular classification of breast cancer. Curr. Opin. Oncol.23 , 93–99 (2011).
- Cicatiello L , MutarelliM, GroberOet al. Estrogen receptor α controls a gene network in luminal-like breast cancer cells comprising multiple transcription factors and microRNAs. Am. J. Pathol. 176 , 2113–2130 (2010).
- Carroll JS , MeyerCA, SongJet al. Genome-wide analysis of estrogen receptor binding sites. Nat. Genet. 38 , 1289–1297 (2006).
- Moggs JG , MurphyTC, LimFLet al. Anti-proliferative effect of estrogen in breast cancer cells that re-express ERα is mediated by aberrant regulation of cell cycle genes. J. Mol. Endocrinol. 34 , 535–551 (2005).
- Sérandour AA , AvnerS, PercevaultFet al. Epigenetic switch involved in activation of pioneer factor FOXA1-dependent enhancers. Genome Res. 21 , 555–565 (2011).
- Yang X , PhillipsDL, FergusonAT, NelsonWG, HermanJG, DavidsonNE. Synergistic activation of functional estrogen receptor (ER)-α by DNA methyltransferase and histone deacetylase inhibition in human ER-α-negative breast cancer cells. Cancer Res.61 , 7025–7029 (2001).
- Sharma D , SaxenaNK, DavidsonNE, VertinoPM. Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. Cancer Res.66 , 6370–6378 (2006).
- Mund C , LykoF. Epigenetic cancer therapy: proof of concept and remaining challenges. Bioessays32 , 949–957 (2010).
- Carroll JS , BrownM. Estrogen receptor target gene: an evolving concept. Mol. Endocrinol.20 , 1707–1714 (2006).
- Fullwood MJ , LiuMH, PanYFet al. An oestrogen-receptor-α-bound human chromatin interactome. Nature 462 , 58–64 (2009).
- Lupien M , MeyerCA, BaileySTet al. Growth factor stimulation induces a distinct ER(α) cistrome underlying breast cancer endocrine resistance. Genes Dev. 24 , 2219–2227 (2010).
- Hurtado A , HolmesKA, Ross-InnesCS, SchmidtD, CarrollJS. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat. Genet.43 , 27–33 (2011).
- Hah N , DankoCG, CoreLet al. A rapid, extensive, and transient transcriptional response to estrogen signaling in breast cancer cells. Cell 145 , 622–634 (2011).
- Maruyama R , ShipitsinM, ChoudhurySet al. Breast cancer special feature: altered antisense-to-sense transcript ratios in breast cancer. Proc. Natl Acad. Sci. USA DOI: 10.1073/pnas.1010559107 (2010) (Epub ahead of print).